Paper Details

  1. Home
  2. Paper Details

A meta-analysis of randomized controlled trials in targeted treatments of chronic thromboembolic pulmonary hypertension.

Author: FanYe, HuangZan-Sheng, LiJing-Meng, XuJian-Cheng, ZhangJing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

Targeted treatments approved for pulmonary arterial hypertension (PAH) are associated with improvement in exercise capacity, haemodynamic parameters, functional status and clinical symptoms in patients with chronic thromboembolic pulmonary hypertension (CTEPH).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) results in a progressively worsening course associated with substantial morbidity and mortality. The purpose of this comprehensive study was to determine the clinical efficacy of targeted therapeutic interventions for this disease. M...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/crj.13034

データ提供：米国国立医学図書館（NLM）

Targeted Treatments for Chronic Thromboembolic Pulmonary Hypertension: A Beacon of Hope

This study, like a caravan navigating a desert of pulmonary hypertension, investigates the effectiveness of targeted treatments for chronic thromboembolic pulmonary hypertension (CTEPH). The researchers conducted a meta-analysis of randomized controlled trials, pooling data from six studies involving 565 patients. The analysis revealed that targeted treatments approved for pulmonary arterial hypertension (PAH) were associated with significant improvements in exercise capacity, hemodynamic parameters, functional status, and clinical symptoms in patients with CTEPH. The findings suggest that PAH-targeted therapies could offer a promising treatment option for CTEPH, potentially improving the quality of life for patients with this challenging condition.

The Promise of PAH-Targeted Therapies for CTEPH

This study highlights the potential of PAH-targeted therapies in treating CTEPH. The findings suggest that these therapies can significantly improve exercise capacity, hemodynamic parameters, functional status, and clinical symptoms, offering a beacon of hope for patients with this challenging condition.

Navigating the Desert of Pulmonary Hypertension

This study provides valuable insights into the treatment of CTEPH. It encourages the further exploration and clinical application of PAH-targeted therapies, potentially leading to improved outcomes for patients with this challenging condition.

Dr.Camel's Conclusion

This study offers a promising oasis in the desert of pulmonary hypertension, highlighting the potential of PAH-targeted therapies in treating CTEPH. The findings encourage further research and clinical application to optimize treatment strategies and improve patient outcomes.
Date :
  1. Date Completed 2020-01-08
  2. Date Revised 2020-01-08
Further Info :

Pubmed ID

31059198

DOI: Digital Object Identifier

10.1111/crj.13034

Related Literature

Article Analysis
・Effective treatment of pulmonary hypertension
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.